Cellectis Biotech Shares Surge Amid Positive Clinical Advances
French biotech company Cellectis saw a significant increase in its stock price, driven by promising clinical trial results and robust trading volumes.
Strong Performance in Recent Trading Sessions
The stock of French biotech Cellectis closed the session on Thursday, December 11, 2025, at 4.57 euros, up 6.65% from the previous day's close of 4.29 euros. This increase occurred in a context of sustained trading volumes, with 0.93% of the capital traded during the day. Over the week, the stock now shows a performance of 14.78%, confirming the acceleration of the upward trend observed in recent days. Over three months, the stock has soared by 78.38%, while the annual performance has reached 148.4%, making Cellectis one of the most successful biotechnological stocks on the Parisian market. This outperformance is part of a broader movement marked by growing investor interest in the company's clinical advancements in genome editing and allogeneic CAR-T therapies.
Promising Preliminary Results from Clinical Trials
The company unveiled on December 8 at the 67th Annual Congress of the American Society of Hematology in Orlando preliminary results of its phase 1 NATHALI-01 clinical trial, with an overall response rate of 88% and a complete response rate of 63% for its candidate product eti-cel. This treatment represents the first allogeneic double CAR candidate simultaneously targeting CD20 and CD22, developed for patients with relapsed or refractory non-Hodgkin lymphoma after at least two lines of treatment. Adrian Kilcoyne, medical director of Cellectis, believes that the addition of low-dose interleukin-2 could deepen the already high response rates observed with eti-cel. The recruitment of the cohort integrating IL-2 will begin in the first quarter of 2026, with a presentation of all phase 1 data expected in 2026. These announcements are a major catalyst for the stock and explain the strength of the rebound observed during the session, as investors applaud the company's clinical development prospects.
Technical Indicators Show Strong Bullish Trend
The stock is trading well above its key moving averages, with a 50-day moving average at 3.58 euros and a 200-day moving average at 2.19 euros, representing respective gaps of 29.1% and 111% below the closing level. This configuration indicates a solidly established bullish trend over the medium and long term. The RSI is at 50, in a neutral zone, leaving room before reaching an overbought situation and suggesting that the movement could continue without excessive tension. The Bollinger Bands frame the stock between 3.36 euros and 4.78 euros, placing the current price in the upper part of the technical corridor. The stock is trading above the major resistance threshold at 4.55 euros, a breakthrough that potentially paves the way for new highs. The one-month volatility stands at 24.30%, a level characteristic of biotechs in the clinical development phase.
